Abstract
Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 5226-5232 |
| Number of pages | 7 |
| Journal | Clinical Cancer Research |
| Volume | 17 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - Aug 15 2011 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. / De Palma, Michele; Naldini, Luigi.
In: Clinical Cancer Research, Vol. 17, No. 16, 15.08.2011, p. 5226-5232.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Angiopoietin-2 TIEs up macrophages in tumor angiogenesis
AU - De Palma, Michele
AU - Naldini, Luigi
PY - 2011/8/15
Y1 - 2011/8/15
N2 - Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed.
AB - Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed.
UR - http://www.scopus.com/inward/record.url?scp=79960638881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960638881&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-10-0171
DO - 10.1158/1078-0432.CCR-10-0171
M3 - Article
C2 - 21576085
AN - SCOPUS:79960638881
VL - 17
SP - 5226
EP - 5232
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 16
ER -